Immune Checkpoint Marker of Programmed Death Ligand-1 (PD-L1) Expression in Surgical Lung Cancer Specimens

Background: Currently immune checkpoint pathways of PD1-PD-L1 is being used to treat lung cancer and PD-L1 served as predictive biomarker. Investigations expression a target immunotherapy in specimens Indonesia needed. This study aimed evaluate resected using immunohistochemistry techniques. Methods: Thirty surgically sample from patients were obtained. The whole stained by techniques automatically BOND-MAX Autostainner (Leica, Germany). polyclonal antibody (Genetex) at 1:1500 dilution was applied staining procedure. Clinicopathological characteristic acquired the hospital registry database.Result: A total 30 surgical assessed patients. Twenty-four (80%) them Adenocarcinoma (AC), 1 (3, 33%) Adenosquamous carcinoma, 2 (6, 67%) Squamous Cell Carcinoma (SSC), Large Carcinoma, Neuroendocrine Adenoid Cyctic Carcinoma. PDL-1 positive reactivity 16 (53.3%) we categorized into strong positivity (>50%), medium (= 50%) low (<50) 21 specimens, 0 7 respectively.Conclusion: could be detected specimen antibody.